DEVICE CATEGORY · SDA
Electrical Tumor Treatment Fields For Non-Small Cell Lung Cancer
Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel is indicated for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Optune LuaP230042/S010 | Novocure, GmbH | PMA supplement | Oct 26, 2026 | FDA |
Optune LuaP230042/S008 | Novocure, GmbH | PMA supplement | Jul 1, 2026 | FDA |
Optune LuaP230042/S007 | Novocure, GmbH | PMA supplement | Feb 25, 2026 | FDA |
Optune LuaP230042/S005 | Novocure, GmbH | PMA supplement | Jan 7, 2026 | FDA |
Optune LuaP230042/S004 | Novocure, GmbH | PMA supplement | Oct 8, 2025 | FDA |
Optune LuaP230042/S001 | Novocure, GmbH | PMA supplement | Aug 12, 2025 | FDA |
Optune LuaP230042 | Novocure, GmbH | PMA approval | Oct 15, 2024 | FDA |
Source information
Follow the FDA links to view the original records.





